MiR-17-92 is Required for the Pathogenicity of T and B Cells in Chronic Gvhd

Yongxia Wu,Steven D. Schutt,Ryan P. Flynn,Mengmeng Zhang,Hung D. Nguyen,Bruce R. Blazar,Xue-Zhong Yu
DOI: https://doi.org/10.1182/blood.v128.22.4535.4535
IF: 20.3
2016-01-01
Blood
Abstract:Chronic graft-versus-host disease (cGVHD) remains to be a major cause of mortality and morbidity after allogeneic hematopoietic cell transplantation (allo-HCT). cGVHD is characterized as autoimmune-like fibrosis and antibody production, mediated by pathogenic T and B cells. Through producing pro-inflammatory cytokines, CD4 T cells are the driving force of cGVHD. Donor B cells augment the pathogenesis of cGVHD not only by acting as antigen-presenting cells (APCs) and promoting CD4 T-cell expansion and survival, but also by producing autoantibodies. microRNA (miR)-17-92 has been shown to regulate T-cell immunity including allogeneic, anti-viral, and anti-tumor responses. Recently, miR-17-92 was found to act together with Bcl-6 to promote the differentiation of Follicular help T (Tfh) cells. Furthermore, B-cell deficiency of miR-17-92 impairs IgG2c production. Since Tfh differentiation and antibody production are required for the development of cGVHD, we hypothesize that miR-17-92 contributes to the pathogenesis of cGVHD by promoting pathogenic T- and B-cell responses.
What problem does this paper attempt to address?